Prevention & lipids

Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study

Circ Popul Health OutcomesPublished randomized, double-blind, phase 3b, placebo-controlled trial

Primary result · Change in log-transformed Lp(a) from baseline (GMR of Lp(a) to baseline)Result — go to the resultGeometric mean ratio 0.14 95% CI 0.11–0.18

Authors' conclusion

This study is the first to demonstrate robust Lp(a) lowering with pelacarsen, which was generally well tolerated, in US Black/African American and Hispanic participants, populations disproportionately impacted by Lp(a)-associated CV risk.

Study context

Population
US Black/African American and Hispanic adults with elevated Lp(a) (≥125 nmol/L) and atherosclerotic cardiovascular disease (ASCVD)analyzed, 423 randomized · 272 (Black/non-Hispanic) · 127 (nonBlack/Hispanic) · 23 (Black/Hispanic)
Participants
422 participants
Comparison
Pelacarsen vs placebo
  • Pelacarsenn = 282
  • Placebon = 140
Primary endpoint
Change in log-transformed Lp(a) from baseline (GMR of Lp(a) to baseline)
Follow-up
Week 52

Primary result

As reported in the abstract

Change in log-transformed Lp(a) from baseline (GMR of Lp(a) to baseline)

Geometric mean ratio

0.14

95% CI 0.11–0.18

P < 0.0001

Change by group

Pelacarsen

0.14

Geometric mean ratio (GMR) to baseline · 95% CI 0.12–0.16

Placebo

0.98

GMR to baseline · 95% CI 0.80–1.20

Pelacarsenvs placebo
GMR 0.14 (95% CI 0.11–0.18); P < 0.0001

Further findings

Trial completion

Safety

TEAEs

Serious TEAEs

TEAE-related treatment discontinuations

Original publication

Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study. Circ Popul Health Outcomes. Published 9 November 2026. doi:10.1161/circoutcomes.126.014453

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.